- Home
- ENTA vs CHN Comparison
ENTA vs CHN Comparison
Compare ENTA & CHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- CHN
- Stock Information
- Founded
- ENTA 1995
- CHN 1992
- Country
- ENTA United States
- CHN United States
- Employees
- ENTA N/A
- CHN N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- CHN Investment Managers
- Sector
- ENTA Health Care
- CHN Finance
- Exchange
- ENTA Nasdaq
- CHN Nasdaq
- Market Cap
- ENTA 160.3M
- CHN 128.4M
- IPO Year
- ENTA 2013
- CHN N/A
- Fundamental
- Price
- ENTA $7.28
- CHN $13.07
- Analyst Decision
- ENTA Buy
- CHN
- Analyst Count
- ENTA 4
- CHN 0
- Target Price
- ENTA $18.00
- CHN N/A
- AVG Volume (30 Days)
- ENTA 168.6K
- CHN 31.8K
- Earning Date
- ENTA 08-04-2025
- CHN 01-01-0001
- Dividend Yield
- ENTA N/A
- CHN 0.19%
- EPS Growth
- ENTA N/A
- CHN N/A
- EPS
- ENTA N/A
- CHN N/A
- Revenue
- ENTA $64,462,999.00
- CHN N/A
- Revenue This Year
- ENTA N/A
- CHN N/A
- Revenue Next Year
- ENTA $0.48
- CHN N/A
- P/E Ratio
- ENTA N/A
- CHN N/A
- Revenue Growth
- ENTA N/A
- CHN N/A
- 52 Week Low
- ENTA $4.09
- CHN $9.00
- 52 Week High
- ENTA $17.24
- CHN $12.98
- Technical
- Relative Strength Index (RSI)
- ENTA 60.14
- CHN 58.19
- Support Level
- ENTA $6.87
- CHN $13.13
- Resistance Level
- ENTA $8.47
- CHN $13.33
- Average True Range (ATR)
- ENTA 0.50
- CHN 0.17
- MACD
- ENTA -0.03
- CHN 0.01
- Stochastic Oscillator
- ENTA 54.44
- CHN 75.70
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.